Ny-eso-1 expressing solid tumors in HLA-A2 positive patients

Clinical trials for Ny-eso-1 expressing solid tumors in HLA-A2 positive patients explained in plain language.

Never miss a new study

Get alerted when new Ny-eso-1 expressing solid tumors in HLA-A2 positive patients trials appear

Sign up with your email to follow new studies for Ny-eso-1 expressing solid tumors in HLA-A2 positive patients, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

Engineered immune cells take on Hard-to-Treat cancers

Disease control Ongoing

This early-phase trial tests a personalized cell therapy called TBI-1301 for people with advanced solid tumors that express a protein called NY-ESO-1. Patients' own T cells are collected, genetically modified in a lab to better recognize and attack cancer cells, and then infused …

Matched conditions: NY-ESO-1 EXPRESSING SOLID TUMORS IN HLA-A2 POSITIVE PATIENTS

Phase 1 • Sponsor: University Health Network, Toronto • Aim: Disease control

Last updated Jun 27, 2026 08:01 UTC

Ny-eso-1 expressing solid tumors in HLA-A2 positive patients

Get alerted when new Ny-eso-1 expressing solid tumors in HLA-A2 positive patients trials appear

Engineered immune cells take on Hard-to-Treat cancers